Loading...
Market
Will Phase 2 clinical trial results for the new small molecule pill for sickle cell disease be published by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Science Magazine or other reputable medical journals
Story
New Small Molecule Pill Offers Safer Treatment for Sickle Cell Disease, Published in Science Magazine
Jul 4, 2024, 06:20 PM
A groundbreaking discovery in the treatment of sickle cell disease has been published in Science Magazine. Researchers have developed a small molecule pill that acts as an epigenetic modifier to inhibit fetal hemoglobin, offering a less dangerous and potentially more accessible alternative to CRISPR genome editing, such as Casgevy. This new approach could open up treatment options globally, reducing the need for toxic conditioning. The study, led by a team including Pamela Ting and Jay Bradner, marks a significant advancement in chemical biology and the development of molecular glue degraders.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
